TempP

cont as TempP(1)

C7592035 ?. Weitere Metaanalyse zu chinesischer Arzneitherapie bei COVID-19.
C7569105 2020. Kortikosteroide senken die 28-Tage-Mortalität.
C7569096 2020. Remdesivir wirkt bei mittelschwerem Verlauf.
C7569089 2020. Konvaleszentenplasma in Abhängigkeit von der IgG-Konzentration wirksam.
C7574989 ?. COVID-19 ? Therapiemöglichkeiten mit chinesischen Arzneimitteln in der Akutphase und Rekonvaleszenz.
C7565236 2020. Multiple drugs: Coronavirus disease 2019 (COVID-19) and lack of efficacy: case report.
C7565230 2020. Azithromycin/hydroxychloroquine: Cardiac disorders following off label use: 5 case reports.
C7565217 2020. Remdesivir-related acute kidney injury in patients with COVID-19.
C7565214 2020. Adalimumab/methotrexate: COVID-19 infection: case report.
C7565212 2020. Favipiravir/hydroxychloroquine/oseltamivir: Tonic clonic seizures following off label use: case report.
C7561306 ?. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab?.
C7549423 ?. Begrenzte Evidenz für chinesische Arzneitherapie bei COVID-19: Systematisches Review und Metaanalyse.
C7547645 2020. Unexpected better outcome in a liver transplant recipient with COVID-19: a beneficial effect of tacrolimus??.
C7546940 2020. Antibacterials/chloroquine/tocilizumab: Kidney and hepatic injury: case report.
C7546932 2020. Favipiravir: Hyperuricaemia and acute gouty arthritis following off-label use: case report.
C7546930 2020. Multiple drugs: Lack of efficacy: case report.
C7546926 2020. Hydroxychloroquine: Allergic reaction in the form of erythema multiforme during off label treatment: case report.
C7546924 2020. Azithromycin/hydroxychloroquine/propofol: Off-label use and propofol infusion syndrome: case report.
C7546922 2020. Cladribine/hydroxychloroquine: COVID-19-pneumonia lymphopenia and off label use: case report.
C7546936 2020. Multiple drugs: Lack of efficacy: case report.
C7546931 2020. Hydroxychloroquine: Sinus bradycardia and QTc prolongation following off-label use: case report.
C7546929 2020. Dexamethasone/prednisone/tocilizumab: Worsening of Strongyloides infection: case report.
C7546925 2020. Avelumab/pembrolizumab: COVID-19 infection and recurrent infusion reactions: case report.
C7538275 ?. Matrix metalloproteinase inhibitors identified from Camellia sinensis for COVID-19 prophylaxis: an in silico approach.
C7538068 ?. Virological cure clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies.
C7530884 2020. Methotrexate: Lack of efficacy: case report.
C7530876 2020. Azithromycin: Wide QRS complex tachyarrhythmia following off-label use: case report.
C7530873 2020. Immunosuppressants/Lopinavir/ritonavir: Elevated drug level Covid 19 and reactivation of Herpes Zoster: 2 case reports.
C7530869 2020. Lopinavir/ritonavir/tocilizumab: Hypertriglyceridaemia following off-label use: 2 case reports.
C7530867 2020. Azithromycin/hydroxychloroquine: QTc interval prolongation: case report.
C7530864 2020. Prednisolone: COVID-19 pneumonia: case report.
C7530852 2020. Lopinavir/ritonavir: Maculopapular rash following off-label use: case report.
C7530849 2020. Hydroxychloroquine: Generalised pustular figurate erythema: 2 case reports.
C7530847 2020. Immunosuppressants: COVID-19 and secondary infections: 3 case reports.
C7530882 2020. Azacitidine: No therapeutic response: case report.
C7530878 2020. Hydroxychloroquine- and chloroquine-related cardiovascular events.
C7530875 2020. Hydroxychloroquine in early pregnancy: risk of birth defects.
C7530871 2020. Multiple drugs: Acute pancreatitis hypertriglyceridaemia and off-label use in coronavirus disease 2019: 2 case reports.
C7530868 2020. Monoclonal antibodies: Impaired humoral immunity: 5 case reports.
C7530857 2020. Multiple drugs: Prolonged viral shedding time and off-label use: case report.
C7530850 2020. Paracetamol: No therapeutic response: case report.
C7530844 2020. Immunosuppressants/CAR T-cell therapies: COVID-19 infection: 2 case reports.
C7548860 2020. CORTICOSTEROID TREATMENT IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.
C7548774 2020. THE USE OF TOCILIZUMAB AT A COMMUNITY HOSPITAL DURING THE COVID-19 PANDEMIC IN THE EPICENTER OF NORTHERN NEW JERSEY.
C7548762 2020. A RECOVERED CASE OF COVID-19 MYOCARDITIS TREATED WITH IV IMMUNOGLOBULIN.
C7548738 2020. THE ASSOCIATION OF IL-6 VALUE INTERLEUKIN INHIBITORS AND OUTCOMES OF PATIENTS WITH COVID-19 IN NEW YORK CITY.
C7548730 2020. COVID-19 VENTILATOR DEPENDENT RESPIRATORY FAILURE SUCCESSFULLY TREATED WITH ANTIINFLAMMATORY BOTANICALS.
C7548673 2020. HYDROXYCHLOROQUINE AND COVID-19: A META-ANALYSIS.
C7548671 2020. TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE.
C7548587 2020. LUNG ABSCESSES IN A PATIENT TREATED WITH TOCILIZUMAB FOR COVID-19 PNEUMONIA COMPLICATED BY SEVERE HYPOXEMIC RESPIRATORY FAILURE.
C7550165 2020. A REMARKABLE RESPONSE TO ANGIOTENSIN II THERAPY IN SEVERE SARS-COV-2 INFECTION.
C7548795 2020. THE ANTI-INFECTIVE AND IMMUNOMODULATOR PARADOX: INCREASED RISK OF COINFECTION WITH HYDROXYCHLOROQUINE IN CRITICAL PATIENTS WITH COVID-19.
C7548775 2020. HEMOLYTIC ANEMIA AND METHEMOGLOBINEMIA DUE TO HYDROXYCHLOROQUINE USE FOR COVID-19 TREATMENT IN A GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT PATIENT.
C7548709 2020. THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19.
C7548682 2020. CONVALESCENT PLASMA THERAPY IN CRITICALLY ILL PATIENTS WITH LATE STAGE COVID-19.
C7548660 2020. IMPROVED SURVIVAL OUTCOME IN PATIENTS WITH SARS-COV-2 (COVID-19) ARDS WITH TOCILIZUMAB ADMINISTRATION.
C7548656 2020. A DRY COUGH CONUNDRUM: A RARE CASE OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENT ON HYDROXYCHLOROQUINE.
C7548636 2020. ANAPHYLACTIC SHOCK IN A PREGNANT PATIENT WITH COVID-19 IN THE SETTING OF CONVALESCENT PLASMA TRANSFUSION.
C7548634 2020. CYTOMEGALOVIRUS COLITIS POST IL-6 INHIBITOR USE IN COVID-19 INFECTION.
C7548624 2020. NITRIC OXIDE IS A POWERFUL ANTI-CORONAVIRUS-INHALED AGENT THAT ACTS WITHIN HOURS.
C7548604 2020. CORONAVIRUS DISEASE 2019 AND CAVEATS OF IMMUNOMODULATORS.
33487301 2021. Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit.
C7543043 ?. The potential of lactoferrin ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19.
C7543042 ?. In silico analysis of protein/peptide-based inhalers against SARS-CoV-2.
C7485645 ?. Use of corticosteroid injections in current COVID pandemic ? Time to rethink!!
C7581319 2020. TCT CONNECT-217 Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval.
C7590838 ?. Combating COVID-19: The role of drug repurposing and medicinal plants.
33491033 ?. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.
C7544924 ?. In silico allicin induced S-thioallylation of SARS-CoV-2 main protease.
C7574546 2020. A new perspective for mitigation of SARS-CoV-2 infection: priming the innate immune system for viral attack.
33380375 ?. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
33485605 ?. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.

C7565225 2020. Rituximab: Prolongation and worsening of COVID-2019-infection: case report.
C7565220 2020. Hydroxychloroquine: Acute generalised exanthematous pustulosis following off-label use: case report.
C7565216 2020. Methotrexate: COVID-19 infection: case report.
C7565201 2020. Methotrexate/methylprednisolone/prednisone: Prolonged SARS-CoV-2 infection and masking of the symptoms of SARS-CoV-2 infection: case report.
C7565239 2020. Tocilizumab: Septic shock following off-label use: case report.
C7565232 2020. Hydroxychloroquine: Acute haemolytic anaemia direct Coombs negative following off-label use: case report.
C7529470 2020. Potential therapeutic target identification in the novel 2019 coronavirus: insight from homology modeling and blind docking study.
C7527303 2020. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
C7556163 2020. Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods.
C7586461 ?. SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.
C7586456 ?. Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles.
C7571299 ?. Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19.
C7571300 ?. Ebselen Disulfiram Carmofur PX-12 Tideglusib and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.
C7553038 ?. Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid.
33496642 2020. Potential role for nitazoxanide in treating SARS-CoV-2 infection.
33349491 ?. Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19?
C7530554 2020. Belief and Usage of Traditional Chinese Medicine as Preventative Measure against COVID-19 Infection During the Pandemic among Chinese Immigrants in Canada.
C7528906 2020. Hydroxychloroquine and Potential Drug Interactions in Older Adults.
C7527307 ?. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.
C7531593 2021. Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU.
C7566798 2020. Inflammation malnutrition and SARS-CoV-2 infection: A disastrous combination?.

33072652 2020. Sudden Death Following Suicide with Colchicine and Chloroquine.
32736876 2020. Propiedades antivirales y antiinflamatorias de ivermectina y su potencial uso en COVID-19.
33341233 2020. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
33049581 2020. The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling.
32621739 2020. Early combination of Tocilizumab and Corticosteroids: An upgrade in anti-inflammatory therapy for severe COVID.
32805024 2020. Implications of COVI-19 antibody dynamics for immunity and convalescent plasma therapy.
33051326 2020. Considerations pour la prise en charge securitaire d'une infection au SRAS-CoV-2 au moyen de chloroquine, d'hydroxychloroquine et d'azithromycine.
33065363 2021. Thioredoxin-albumin fusion protein prevents urban aerosol-induced lung injury via suppressing oxidative stress-related neutrophil extracellular trap formation.
33067760 2020. Child behaviour during dental care under nitrous oxide sedation: a cohort study using two different gas distribution systems.
33117508 2020. Prospects of plasmapheresis for patients with severe COVID-19.
33133107 2020. Editorial: Immune-Modulatory Effects of Vitamin D.
33117343 2020. Azithromycin Differentially Alters TCR-Activated Helper T Cell Subset Phenotype and Effector Function.
33015114 2020. Editorial: Nutrition, Immunity and Viral Infections.
33132549 2020. Tocilizumab and COVID-19.
33061476 2020. Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report.
32916818 2020. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.
32911795 2020. An Update on Vitamin D Metabolism.
33042489 2020. Can Zinc Be an Option for Prevention of Corona Virus Disease 2019?
32869923 2020. A biflavonoid-rich extract from Selaginella moellendorffii Hieron. induces apoptosis via STAT3 and Akt/NF-kappaB signalling pathways in laryngeal carcinoma.
33071519 2020. Repurposing Hepatitis C Direct -acting antivirals against COVID-19.
33111199 2021. Bacillus Calmette-Guerin (BCG) Vaccine-associated Complications in Immunodeficient Patients Following Stem Cell Transplantation.
32932587 2020. Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations.
32858837 2020. Understanding the Relationship between Glutathione, TGF-beta, and Vitamin D in Combating Mycobacterium tuberculosis Infections.
33073066 2021. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD.
33078031 2021. Optimizing the production of vitamin D in white button mushrooms (Agaricus bisporus) using ultraviolet radiation and measurement of its stability.
33122970 2020. Luteolin Attenuates IL-1beta-Induced THP-1 Adhesion to ARPE-19 Cells via Suppression of NF-kappaB and MAPK Pathways.
32967141 2020. Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines.
33296987 2020. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
33009505 2020. Convalescent plasma trial shows no benefit.
32933052 2020. Clinical Significance of Analysis of Vitamin D Status in Various Diseases.
32931286 2020. Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis.
32867272 2020. Kinins and Their Receptors in Infectious Diseases.
32937880 2020. Immunostimulating RNA Delivered by P1500 PEGylated Cationic Liposomes Limits Influenza Infection in C57Bl/6 Mice.
33026598 2020. Role of vitamin D in diabetic retinopathy: Pathophysiological and clinical aspects.
33052207 2020. Remdesivir : forme inhalee en pediatrie.
32842641 2020. Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview.

33515005 2021. Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank.
33399201 2021. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
33399186 2021. Importance of the Lipid-Bound Character of Vitamin D Binding Protein in the Evaluation of Vitamin D Status in COVID-19 Patients.
33483744 2021. Developing statewide remdesivir use criteria.
33493729 2021. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.
33410395 2021. COVID-19 and Corticosteroids: Unfamiliar but Potentially Fatal Infections That Can Arise following Short-Course Steroid Treatment.
33508271 2021. Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies.
33469977 2021. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein.
33464672 2021. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
33387615 2021. Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab.
33420963 2021. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients.
33395345 2021. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.
33395339 2021. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose.
33460347 2021. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.
33456770 2021. Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis.
33520220 2021. When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19.
33489115 2021. Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.
33440983 2021. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
33381234 2020. Low-dose radiation therapy for coronavirus disease-2019 pneumonia: Is it time to look beyond apprehensions?
33440681 2021. Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets.
33401749 2021. Role of Melatonin on Virus-Induced Neuropathogenesis-A Concomitant Therapeutic Strategy to Understand SARS-CoV-2 Infection.
33515606 2021. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
33444702 2021. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
33422611 2021. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
33512610 2021. Apoptosis induced by SARS-CoV-2: can we target it?
33512650 2021. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
33519322 2021. Drug repositioning based on similarity constrained probabilistic matrix factorization: COVID-19 as a case study.
33485847 2021. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.
33483203 2020. Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19".
33389097 2021. Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China.
33485639 2020. New COVID-19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis.
33380359 2020. COVID-19 Vaccines: New Developments and the Road Ahead.
33459817 2021. Addressing the potential role of curcumin in the prevention of COVID-19 by targeting the Nsp9 replicase protein through molecular docking.
33398691 2021. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.
33492523 2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
33457430 2021. Chemical profiling of selected Ayurveda formulations recommended for COVID-19.
33483287 2021. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?
33454058 2021. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
33388129 2021. Remdesivir: From Ebola to COVID-19.
33387885 2021. In silico study of the potential interactions of 4'-acetamidechalcones with protein targets in SARS-CoV-2.
33477032 2021. ATP biphasically modulates LLPS of SARS-CoV-2 nucleocapsid protein and specifically binds its RNA-binding domain.
33515531 2021. PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.
33482149 2021. Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.
33439253 2021. Antivirals that target the host IMPalpha/beta1-virus interface.
33469510 2021. A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines.
33381848 2020. FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2.
33409924 2021. Olfactory Disturbances as Presenting Manifestation Among Egyptian Patients with COVID-19: Possible Role of Zinc.
33513850 2021. Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2.
33508618 2021. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19.
33486202 2021. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.
33378989 2021. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
33486212 2021. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines.
33454595 2021. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators.
33426074 2020. Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues.
33424013 2021. Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit.
33430299 2021. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
33445810 2021. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
33396926 2020. Potential Medicinal Plants for the Treatment of Dengue Fever and Severe Acute Respiratory Syndrome-Coronavirus.
33450541 2021. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.
33515918 2021. Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking.
33458647 2021. Review of pharmacologic and immunologic agents in the management of COVID-19.
33390423 2021. Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?
33390384 2021. Latest updates on COVID-19 vaccines.
33443562 2021. Vaccinations in CLL: implications for COVID-19.
33478471 2021. Allergen fragrance molecules: a potential relief for COVID-19.
33446136 2021. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.
33430799 2021. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.
33413329 2021. Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2.
33482902 2021. A pilot trial of human amniotic fluid for the treatment of COVID-19.
33472855 2021. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
33419750 2021. Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab.
33509890 2021. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.
33472840 2021. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis.
33504571 2021. Does vitamin D supplementation prevent SARS-CoV-2 infection in military personnel? Review of the evidence.
33521556 2020. Micronutrient deficiencies in patients with COVID-19: how metabolomics can contribute to their prevention and replenishment.
33521536 2020. Responsibility for vitamin D supplementation of elderly care home residents in England: falling through the gap between medicine and food.
33441373 2021. Rationale for azithromycin in COVID-19: an overview of existing evidence.
33483637 2021. Oral side effects of COVID-19 vaccine.
33454964 2021. Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality.
33524158 2021. Convalescent plasma for COVID-19 - encouraging signals of efficacy.
33482025 2021. Early mortality benefit with COVID-19 convalescent plasma: a matched control study.
33504378 2021. Optimising COVID-19 vaccine efficacy by ensuring nutritional adequacy.
33468263 2021. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2.
33518836 2021. Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report.
33497434 2021. Identifying anti-coronavirus peptides by incorporating different negative datasets and imbalanced learning strategies.
33480398 2021. DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses.
33461215 2021. Ligand-based approach for predicting drug targets and for virtual screening against COVID-19.
33406222 2021. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.
33406218 2021. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
33497123 2021. Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.
33517757 2021. Clozapine Intoxication in COVID-19.
33439703 2021. The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines.
33416244 2020. Effects of Hydroxychloroquine With or Without Azithromycin on QT Interval in COVID-19: A Systematic Review. Electrophysiology Collaborative Consortium for Meta-analysis-Electram Investigators.
33481405 2021. Aspirin in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome: An Old, Low-Cost Therapy With a Strong Rationale.
33395337 2021. WHO recommends corticosteroids for patients with severe or critical COVID-19.
33395331 2021. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
33524290 2021. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 >/=7 days after the 2nd dose.
33524282 2021. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a differed from standard care for in-hospital mortality.
33524280 2021. Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.
33509798 2021. Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine by Perricone et al.
33509794 2021. Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'.
33504481 2021. Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'.
33504480 2021. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome by Kawada.
33452005 2021. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
33459727 2020. Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment.
33472834 2021. Covid-19: Arthritis drug trial for severe illness is stopped early after increase in deaths.
33446489 2021. Covid-19: Convalescent plasma may cut deaths in patients not on ventilation, study indicates.
33436419 2021. How the Oxford-AstraZeneca covid-19 vaccine was made.
33455917 2021. Cyclosporine: hope for severe COVID-19?
33401333 2021. COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31.
33512003 2021. Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence.
33502877 2021. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19?

33521606 2021. Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review.
33481336 2021. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana.
33430659 2021. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
33513419 2021. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
33485971 2021. Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification.
33485973 2021. Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.
33514385 2021. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
33426604 2021. ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy.
33403500 2021. Pharmacotherapeutics of SARS-CoV-2 Infections.
33491033 2021. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.
33491026 2021. Editorial: COVID19 Vaccination in Frail People. Lots of Hope and Some Questions.
33398242 2021. Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities.
33456225 2020. A brief outlook on the current emerging trends of COVID 19 vaccines.
33388760 2021. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents.
33495677 2021. Comments on potential re-purposing of medicines against high-altitude illnesses towards SARS-CoV2: possibilities and pitfalls.
33472369 2021. ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.
33439850 2021. Diet, Nutrition, Obesity, and Their Implications for COVID-19 Mortality: Development of a Marginalized Two-Part Model for Semicontinuous Data.
33437926 2021. A Call to Action: "Low-Dose Radiation May Help Cure COVID-19..." [Taps Mic] "...Is This Thing On?"
33437924 2021. Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls.
33390434 2020. Increased secondary infection in COVID-19 patients treated with steroids in New York City.
33485468 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
33485467 2021. Optimism and caution for an inactivated COVID-19 vaccine.
33493450 2021. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
33493449 2021. The right place for IL-1 inhibition in COVID-19.
33484632 2021. Realising the potential of SARS-CoV-2 vaccines-a long shot?
33460572 2021. Assessing the importance of interleukin-6 in COVID-19 - Authors' reply.
33460569 2021. Assessing the importance of interleukin-6 in COVID-19.
33461387 2021. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
33476632 2021. Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.
33513400 2021. Cardiovascular protective properties of oxytocin against COVID-19.
33402630 2021. Is there a role for inhaled ciclesonide in the treatment of COVID-19?
33513822 2021. Caged Dexamethasone/Quercetin Nanoparticles, Formed of the Morphogenetic Active Inorganic Polyphosphate, are Strong Inducers of MUC5AC.
33413833 2021. Inverse Relationship of Maximal Exercise Capacity to Hospitalization Secondary to Coronavirus Disease 2019.
33413825 2021. Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.
33413824 2021. In Reply - Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.
33419872 2021. Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV.
33468703 2021. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.
33424100 2020. Physical Activity Outdoors as an Alternative to Lockdown: the Three Cs Strategy.
33388144 2021. Reaccion transfusional a plasma hiperinmune en pacientes con infeccion grave por COVID-19.
33380371 2021. Efectividad de los glucocorticoides en pacientes hospitalizados por neumonia grave por SARS-CoV-2.
33392390 2021. Relationship between MMR vaccination and severity of Covid-19 infection. Survey among primary care physicians.
33422363 2021. Tackling the COVID-19 "cytokine storm" with microRNA mimics directly targeting the 3'UTR of pro-inflammatory mRNAs.
33385879 2021. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".
33385878 2021. The plausible mechanisms of tramadol for treatment of COVID-19.
33485026 2021. Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients.
33482620 2021. Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy.
33460992 2021. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
33421690 2021. Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow(R) be used as an antiplatelet regime?
33505216 2021. Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids.
33481741 2020. La bioseguridad de las vacunas anti-COVID-19.
33481727 2020. Plasma de convalecientes como terapia para la neumonia por COVID-19 grave.
33429732 2021. Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience.
33453392 2021. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
33482357 2021. Could targeting immunometabolism be a way to control the burden of COVID-19 infection?
33430200 2021. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.
33451069 2021. Development of Coronavirus Treatments Using Neutralizing Antibodies.
33402220 2021. SARS-CoV-2: vaccines in the pandemic era.
33464512 2021. Anaphylaxie-Risiko bei der COVID-19-Impfung: Empfehlungen fur das praktische Management.
33507892 2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
33444297 2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
33382675 2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.
33464543 2021. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
33400086 2021. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.
33400085 2021. First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery.
33398633 2021. Identification of novel inhibitors of angiotensin-converting enzyme 2 (ACE-2) receptor from Urtica dioica to combat coronavirus disease 2019 (COVID-19).
33389560 2021. CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy.
33389441 2021. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
33492566 2021. Computational assessment of saikosaponins as adjuvant treatment for COVID-19: molecular docking, dynamics, and network pharmacology analysis.
33389440 2021. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.
33503834 2021. Antiviral Activity of Jamaican Medicinal Plants and Isolated Bioactive Compounds.
33467029 2021. Natural and Nature-Derived Products Targeting Human Coronaviruses.
33466743 2021. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
33500564 2021. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes.
33471984 2021. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.
33440088 2021. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
33440086 2021. (A Little) Clarity on Convalescent Plasma for Covid-19.
33406353 2021. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
33391623 2020. Manganese nanodepot augments host immune response against coronavirus.
33418136 2021. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome.
33510133 2021. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.
33483491 2021. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
33473140 2021. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.
33473130 2021. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery.
33446655 2021. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
33436624 2021. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
33436577 2021. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
33436573 2021. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
33431876 2021. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
33431856 2021. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
33432129 2021. Immune readouts from the Oxford COVID-19 vaccine.
33394134 2021. NF-kappaB signalling as a pharmacological target in COVID-19: potential roles for IKKbeta inhibitors.
33416933 2021. Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
33443616 2021. Efficacy of synthetic glucocorticoids in COVID-19 endothelites.
33425362 2021. Oral probiotics in coronavirus disease 2019: connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials.
33495468 2021. Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.
33495451 2021. The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guerin vaccine.
33435521 2021. Magnesium in Infectious Diseases in Older People.
33498631 2021. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro.
33466642 2021. Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study.
33419325 2020. Nutritional and Behavioral Approaches to Body Composition and Low-Grade Chronic Inflammation Management for Older Adults in the Ordinary and COVID-19 Times.
33412367 2021. Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases.
33456092 2021. COVID-19: Analysis of Drug Repositioning Practice.
33445955 2021. Repurposing drugs during the COVID-19 pandemic and beyond.
33430081 2021. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.
33419184 2021. Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2.
33455739 2021. Inmunomodulacion mediante CONVEHY(R) para COVID-19: de la tormenta al anticiclon de citoquinas.
33493900 2021. Carrying out pseudo dual nucleic acid detection from sample to visual result in a polypropylene bag with CRISPR/Cas12a.
33419743 2021. Covid-19: Arthritis drugs improve survival in intensive care patients, shows study.
33408068 2021. Covid-19 vaccination: What's the evidence for extending the dosing interval?
33514589 2021. Increasing recruitment into covid-19 trials.
33428504 2021. Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
33497594 2021. The Potential Role of Photobiomodulation in Long COVID-19 Patients Rehabilitation.

33476998 2021. Predictive value of the prognostic nutritional index for the severity of coronavirus disease 2019.
33450678 2021. Micronutrients and bioactive substances: Their potential roles in combating COVID-19.
33421827 2021. Sarcopenia: An underlying treatment target during the COVID-19 pandemic.
33418230 2021. Increased risk for COVID-19 in patients with vitamin D deficiency.
33426364 2021. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment.
33408570 2020. Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials.
33426262 2021. Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.
33506065 2021. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.
33425070 2020. BCG Vaccine does not Protect Against COVID-19.
33456654 2020. Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report.
33456653 2020. Promotion of unproved and potential dangerous measures in fighting COVID-19 pandemic: urgent need for vigilant appropriate public communication and generation of scientific evidence.
33425157 2020. A review of COVID-19 vaccines in development: 6 months into the pandemic.
33480519 2021. Why two doses of the BNT162b2 mRNA Covid-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA Covid-19 and other vaccines.
33504008 2021. Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach.
33477294 2021. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.
33435273 2021. Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters.
33437147 2021. Effects on LOS may not justify cost of remdesivir for severe COVID-19.
33389725 2021. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
33389724 2021. SARS-CoV-2 therapeutics: how far do we stand from a remedy?
33421347 2021. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.
33515763 2021. A combination of phototherapy modalities for extensive lip lesions in a patient with SARS-CoV-2 infection.
33422697 2021. Can photodynamic therapy be repurposed to treat oral lesions of COVID-19?
33463909 2021. 17beta-estradiol reduces SARS-CoV-2 infection in vitro.
33485605 2020. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.
33380375 2020. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
33419674 2020. Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT).
33495692 2021. Localized Plasmonic Photothermal Therapy as a Life-saving Treatment Paradigm for Hospitalized COVID-19 Patients.
33382685 2020. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.
33395417 2021. Zinc against COVID-19? Symptom surveillance and deficiency risk groups.
33507958 2021. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response.
33497420 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.
33493227 2021. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein.
33481950 2021. Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice.
33444408 2021. Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study.
33417604 2021. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).
33411791 2021. Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.
33406138 2021. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
33382734 2020. The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.
33465165 2021. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.
33382547 2021. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.
33481361 2020. Polymers with antiviral properties: A brief review.
33481360 2020. Focus on COVID-19: Antiviral polymers in drugs and vaccines.
33452205 2021. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection.
33390763 2021. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients.
33516093 2021. Blood omega-3 fatty acids and death from COVID-19: A pilot study.
33420956 2021. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow.
33387249 2021. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
33392622 2021. Fluvoxamine, melatonin and COVID-19.
33465426 2021. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.
33489300 2020. Vitamin D and COVID-19: evidence and recommendations for supplementation.
33415646 2021. Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction.
33461535 2021. Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.
33399672 2020. Corticoides para el tratamiento de COVID-19.
33388902 2021. Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19.
33386447 2021. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.
33447107 2021. Effects of Vitamin D on COVID-19 Infection and Prognosis: A Systematic Review.
33458569 2021. Re-reading ACT, BCG, and Low COVID-19 in Africa.
33503560 2021. Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach.
33514427 2021. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
33511519 2021. Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis.
33511518 2021. Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.
33432484 2021. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.
33423157 2021. Stem Cells as Potential Therapeutics and Targets for Infection by COVID19 - Special Issue on COVID19 in Stem Cell Reviews and Reports.
33415541 2021. Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients.
33414832 2020. Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2.
33400390 2021. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
33502567 2021. COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.
33437137 2021. Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study.
33382449 2020. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
33408775 2021. The 2020 race towards SARS-CoV-2 specific vaccines.
33391531 2021. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
33391497 2021. Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein.
33433109 2021. Kortikosteroider til sykehjemspasienter med covid-19?
33428032 2021. Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.
33484708 2021. Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.
33425684 2021. Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions.
33478889 2021. A look-back at convalescent plasma to treat COVID-19.
33461918 2021. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
33388249 2021. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
33462569 2021. The Intersection of Photopheresis and COVID-19 Vaccination.
33515686 2021. Could shear stress mimetics delay complications in COVID-19?
33424125 2021. Polysaccharides obtained from natural edible sources and their role in modulating the immune system: Biologically active potential that can be exploited against COVID-19.
33446406 2021. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.
33505872 2021. Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.
33441235 2021. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.
33478794 2021. Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).
33478787 2021. Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
33429880 2021. Current State of the First COVID-19 Vaccines.
33406785 2021. SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead.
33513693 2021. COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population.
33499326 2021. Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy.
33494530 2021. Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate.
33494381 2021. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.
33478109 2021. Nanomaterial Delivery Systems for mRNA Vaccines.
33440794 2021. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?
33440640 2021. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.
33396667 2020. Plant-Based Drugs and Vaccines for COVID-19.
33394351 2020. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
33421743 2021. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
33387788 2021. Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2.
33503819 2021. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
33498923 2021. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL(pro) Inhibitors.
33477902 2021. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
33477376 2021. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
33466921 2021. Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.
33451132 2021. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
33396343 2020. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.
33396594 2020. PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity.
33396578 2020. Interferon-alpha2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities.
33425204 2021. Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases.
33386950 2021. COVID-19 and BCG: where's the challenge?
33438061 2021. Impfung gegen SARS-CoV-2 bei entzundlich rheumatischen Erkrankungen : Empfehlungen der DGRh fur Arzte und Patienten.

33440401 2021. Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses.
33386025 2021. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.
33456058 2021. Les vaccins a ARN anti-COVID-19.
33495684 2021. Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak.
33503163 2021. Reacoes adversas a medicamentos em pacientes com COVID-19 no Brasil: analise das notificacoes espontaneas do sistema de farmacovigilancia brasileiro.
33404925 2021. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.
33387252 2021. QTc Prolongation in COVID-19 Patients Using Chloroquine.
33425407 2020. The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis.
33425279 2020. Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19.
33425262 2020. A brief review of the latest pharmacological treatments of COVID-19.
33479399 2021. COVID-19 vaccines: where we stand and challenges ahead.
33421384 2021. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19.
33488836 2021. Engineered Aptamers for Enhanced COVID-19 Theranostics.
33521696 2021. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.
33473156 2021. Dalbavancin: novel candidate for COVID-19 treatment.
33522308 2021. Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.
33502716 2021. Effective treatment with Tocilizumab in a COVID-19 patient on maintenance hemodialysis: A case report.
33462575 2021. Mass spectrometry reveals potential of beta-lactams as SARS-CoV-2 M(pro) inhibitors.
33424029 2021. Synthetic strategies for pyrrolo[2,1-f][1,2,4]triazine: the parent moiety of antiviral drug remdesivir.
33519023 2021. Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease.
33518774 2021. Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies.
33518775 2020. Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: A molecular docking study.
33518858 2020. Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study.
33453180 2021. A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
33493441 2021. Surfactant for the Treatment of ARDS in a Patient With Coronavirus Disease 2019.
33422222 2021. Zinc and Coronavirus Disease 2019: Causal or Casual Association?
33420601 2021. Chinese Medicine in Fighting against Covid-19: Role and Inspiration.
33489151 2021. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.
33521390 2021. Antivirals for COVID-19: A critical review.
33486146 2021. Unilateral axillary Adenopathy in the setting of COVID-19 vaccine.
33429060 2021. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases".
33515458 2021. Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model.
33515255 2021. The Olympiad of SARS-CoV-2 vaccinology: Fundamentals to Complement Technical Frontiers.
33515253 2021. Tocilizumab in COVID-19: Give it time!
33515252 2021. The impact of vaccination on COVID-19 outbreaks in the United States.
33503230 2021. The case against delaying SARS-CoV-2 mRNA vaccine boosting doses.
33503229 2021. Antioxidant therapy in COVID-19: The crucial role of early treatment and antioxidant typology.
33502467 2021. Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.
33493302 2021. Making sense of contradictory evidence in Covid-19 trials.
33402859 2020. Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis.
33476807 2021. Prophylaxis for COVID-19: a systematic review.
33380357 2020. Association between iron status and the risk of adverse outcomes in COVID-19.
33487301 2021. Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit.
33487263 2021. Anthropometric assessment in ambulatory nutrition amid the COVID-19 pandemic: Possibilities for the remote and in-person care.
33402269 2021. Optimal Timing for COVID-19 Vaccination in Oncology Patients Receiving Chemotherapy?
33501997 2021. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
33406317 2021. Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell.
33520676 2021. Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles.
33520528 2020. High Dose Steroid Therapy to Prevent Severe Hypoxia in COVID-19 Patients: A Potential Solution for Low Resource Clinical Setting.
33486832 2021. Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.
33406308 2021. Cutaneous manifestations of COVID-19: An unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications.
33403227 2020. Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.
33402882 2020. Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China.
33496060 2021. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.
33499310 2021. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
33494244 2021. Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination.
33451007 2021. Favipiravir in Therapy of Viral Infections.
33447309 2020. COVID-19 and Possible Pharmacological Preventive Options.
33426360 2020. Anti-tumor necrosis factor agents and COVID-19: A word of caution.
33450319 2021. Development of nanoparticle-delivery systems for antiviral agents: A review.
33439960 2021. Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review.
33424398 2021. In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2.
33424377 2021. Probiotics, prebiotics, and COVID-19 infection: A review article.
33457042 2021. A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional chinese medicines.
33471276 2021. Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19.
33441564 2021. Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection.
33420186 2021. ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.
33483539 2021. First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles.
33479401 2021. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.
33479261 2021. Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperature-humidity, pointing to vitamin D as contributing factor.
33446817 2021. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.
33441985 2021. Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors.
33441909 2021. Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients.
33436985 2021. Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2.
33436946 2021. The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning.
33425427 2020. Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (M(pro)) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study.
33514688 2021. Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis.
33423577 2021. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.
33457315 2020. The Many Faces of Covid-19: Organizing Pneumonia (OP) Pattern HRCT Features.
33504502 2021. Covid-19 controversies: the tocilizumab chapter.
33500251 2021. Covid-19: Moderna plans booster doses to counter variants.
33483332 2021. Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected.
33381648 2020. Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs.
33445938 2020. Ročni obdobi, vitamin D a COVID-19.
33386649 2021. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19.
33443248 2021. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.
33524090 2021. Antiviral drug discovery: preparing for the next pandemic.
33434052 2021. DAMPening Mortality in COVID-19: Therapeutic Insights From Basic Cardiometabolic Studies on S100A8/A9.
33394522 2021. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients.
33480877 2021. Convalescent Plasma: Education and Administration Implications.
33480870 2021. COVID-19 Vaccines: Preparing for Vaccination in the Context of Clinical Oncology Care.
33410139 2021. Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics.
33410134 2021. Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.
33480424 2021. Host cell glutamine metabolism as a potential antiviral target.
33404204 2021. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.
33404133 2021. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.
33403775 2021. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
33441063 2021. Deep learning in the quest for compound nomination for fighting COVID-19.
33509001 2021. The nutritional status of the elderly patient infected with COVID-19: the forgotten risk factor?
33504301 2021. Phenylbenzopyrone of flavonoids as a potential scaffold to prevent SARS-CoV-2 replication by inhibiting its MPRO main protease.
33459226 2021. Therapeutic agents against COVID-19 with clinical evidence.
33459225 2021. Natural agents modulating ACE-2: A review of compounds with potential against SARS-CoV-2 infections.
33430748 2021. In silico Prediction and Designing of Potential siRNAs to be Used as Antivirals Against SARS-CoV-2.
33430746 2021. Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical based Evidence.
33388014 2021. Use of Natural Compounds as a potential therapeutic agent against COVID-19.
33438550 2021. Regenerative Medicine Approaches in COVID -19 Pneumonia.
33463470 2021. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
33497492 2021. A finding associated with favipiravir-associated photosensitivity: Yellow-green fluorescence in the lunulae, scalp, and face.
33517789 2021. Study on mechanism of matrine in treatment of COVID-19 combined with liver injury by network pharmacology and molecular docking technology.
33401328 2021. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.
33513649 2021. Steroide in der Infektionsmedizin.
33459251 2021. The Role of Nutrition during the COVID-19 Pandemic: What We Know.

33520579 2021. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
33500874 2021. Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19).
33457176 2021. Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis.
33457172 2021. Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches.
33457171 2021. In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2.
33417425 2021. Early Returns on Small Molecule Therapeutics for SARS-CoV-2.
33479570 2021. Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
33480671 2021. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles.
33464829 2021. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
33398250 2020. Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease.
33456449 2021. Complexity analysis of cold chain transportation in a vaccine supply chain considering activity inspection and time-delay.
33422546 2021. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
33421475 2021. Recombinant protein vaccines, a proven approach against coronavirus pandemics.
33400957 2021. Self-assembled mRNA vaccines.
33428995 2021. Nanocarrier vaccines for SARS-CoV-2.
33482248 2021. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
33465451 2021. In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives.
33491915 2021. Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity.
33458958 2021. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.
33520645 2021. Vitamin-D and COVID-19: time for the profession to take a stand.
33520646 2020. The potential contribution of traditional, complementary and integrative treatments in acute viral respiratory tract infections: Rapid Reviews in response to the COVID-19 pandemic.
33439972 2021. Western Dietary Pattern Antioxidant Intakes and Oxidative Stress: Importance During the SARS-CoV-2/COVID-19 Pandemic.
33471354 2021. A review of Ciclesonide in COVID-19. Still a long way to go.
33393643 2020. Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience.
33465050 2021. Fighting the storm: could novel anti-TNFalpha and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?
33489449 2020. TaibUVID nutritional supplements help rapid cure of COVID-19 infection and rapid reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and treatment of COVID-19 pandemic.
33415017 2020. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.
33417877 2021. Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19.
33489475 2020. Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.
33502950 2021. Soluble ACE2 as a potential therapy for COVID-19.
33404354 2021. Exploring the link between vitamin D and clinical outcomes in COVID-19.
33404365 2021. Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19.
33496642 2020. Potential role for nitazoxanide in treating SARS-CoV-2 infection.
33437355 2020. Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?
33397585 2021. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
33484986 2021. Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective.
33390567 2021. Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic.
33385574 2021. Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions.
33422991 2021. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
33418497 2021. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19.
33495752 2021. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
33521339 2021. Multiple sclerosis, B cell therapy, and the COVID-19 vaccine.
33520331 2020. The Scientific Foundation of Chinese Herbal Medicine against COVID-19.
33472816 2021. Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
33520016 2021. COVID-19, prevention and treatment with herbal medicine in the herbal markets of Sale Prefecture, North-Western Morocco.
33520014 2021. Two pronged approach for prevention and therapy of COVID-19 (Sars-CoV-2) by a multi-targeted herbal drug, a component of ayurvedic decoction.
33520015 2020. Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.
33524687 2021. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic.
33508085 2021. Is COVID-19 lockdown associated with vitamin D deficiency?
33506949 2021. Quinacrine as a potential treatment for COVID-19 virus infection.
33506948 2021. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.
33506946 2021. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
33504238 2021. Tocilizumab for the treatment of COVID-19.
33475441 2021. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.
33499687 2021. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
33435759 2021. Immunoinformatics-guided designing and in silico analysis of epitope-based polyvalent vaccines against multiple strains of human coronavirus (HCoV).
33435774 2021. COVID-19 vaccine: where are we now and where should we go?
33443475 2021. Remdesivir y reduccion de mortalidad en pacientes con COVID-19: analisis sistematizado de subgrupos de los ensayos clinicos.
33449359 2021. Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein.
33520970 2020. Perinatal Cells: A Promising COVID-19 Therapy?
33520943 2020. In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate.
33521056 2020. In vitro Dissolution Profile at Different Biological pH Conditions of Hydroxychloroquine Sulfate Tablets Is Available for the Treatment of COVID-19.
33521032 2020. Predictive Value of Prognostic Nutritional Index on COVID-19 Severity.
33472895 2021. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
33462654 2021. Impfempfehlungen der Standigen Impfkommission (STIKO) : Impfungen bei Immundefizienz und Impfung gegen COVID-19.
33482433 2021. Is prognostic nutritional index a predictive marker for estimating all-cause in-hospital mortality in COVID-19 patients with cardiovascular risk factors?
33467131 2021. Can Optimum Solar Radiation Exposure or Supplemented Vitamin D Intake Reduce the Severity of COVID-19 Symptoms?
33524396 2021. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.
33416020 2021. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.
33413032 2021. Identification of potential SARS-CoV-2 M(pro) inhibitors integrating molecular docking and water thermodynamics.
33403946 2021. In silico design of multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein.
33509045 2021. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2.
33491579 2021. Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.
33491569 2021. RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2.
33427102 2021. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
33474735 2021. AAMC Discusses Monoclonal Antibody Therapeutics for SARS-CoV-2 Infection.
33511638 2021. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.
33491508 2021. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro.
33442304 2021. Experimental Pharmacotherapy for COVID-19: The Latest Advances.
33391636 2020. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus.
33458853 2021. Potential health benefits of zinc supplementation for the management of COVID-19 pandemic.
33380377 2020. Vaccine efficacy against COVID-19: A foresight on the host-associated factors.
33519145 2021. Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study.
33519144 2021. Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review.
33464639 2021. Role of vitamin D in regulating COVID-19 severity-An immunological perspective.
33523654 2021. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
33512007 2021. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease.
33503267 2021. Oxygen-ozone autohemotherapy against COVID-19 needs to fit highly experienced, customized, and standardized protocols to succeed.
33475170 2021. Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients.
33475167 2021. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
33511655 2021. Early remdesivir treatment in COVID-19: Why wait another day?
33448426 2021. Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019.
33493301 2021. Available drugs and supplements for rapid deployment for treatment of COVID-19.
33516966 2021. A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic.
33518856 2021. A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds.
33518854 2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part II: Complexation with several pi-acceptors (PA, CLA, CHL).
33395259 2021. Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses.
33468299 2021. Vacina para a COVID-19: Da Teoria a Pratica.
33523540 2021. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
33504509 2021. Is sitagliptin effective for the treatment of COVID-19?
33386655 2021. Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective.
33423554 2021. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.
33400393 2021. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
33448695 2020. Vitamin D to prevent COVID-19: recommendations for the design of clinical trials.
33491580 2021. Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.
33491573 2021. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.
33459176 2021. Molecular docking and simulation studies of natural compounds of Vitex negundo L. against papain-like protease (PL(pro)) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world.
33459174 2021. Withanolides from Withania somnifera as an immunity booster and their therapeutic options against COVID-19.
33433137 2021. Pandemic aspect of dexamethasone: Molecular mechanisms and clinical application.
33504214 2021. A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic.
33507143 2021. Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19.
33386773 2021. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice.

33426632 2021. COVID-19 vaccination in immunocompromised patients.
33503192 2021. Antiviral activity of Brazilian Green Propolis extract against SARS-CoV-2 (Severe Acute Respiratory Syndrome - Coronavirus 2) infection: case report and review.
33504561 2021. Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making.
33408097 2021. Remdesivir for patients with COVID-19.
33473151 2021. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
33505639 2021. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
33398234 2021. Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering.
33391634 2021. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2.
33391633 2021. Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?
33422642 2021. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.
33495742 2021. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.
33397463 2021. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.
33490955 2021. Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis.
33437559 2021. Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis.
33425565 2021. The Flu Vaccination May Have a Protective Effect on the Course of COVID-19 in the Pediatric Population: When Does Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Meet Influenza?
33409034 2020. Treatment Experience With Inhaled Corticosteroids in Combination with Remdesivir and Dexamethasone Among COVID-19 Patients Admitted to a Rural Community Hospital: A Case Series.
33409026 2020. The Role of Vitamin C as Adjuvant Therapy in COVID-19.
33510989 2020. Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale.
33489621 2020. Is There any Additional Benefit of Multiple Doses of Tocilizumab in COVID-19 Patients?
33475900 2021. Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.
33409442 2020. COVID-19 and Telenutrition: Remote Consultation in Clinical Nutrition Practice.
33390762 2021. Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker.
33403480 2021. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.
33457366 2020. Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection.
33415491 2021. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.
33439342 2021. A novel approach to managing COVID-19 patients: results of lopinavir plus doxycycline cohort-authors' reply.
33404753 2021. Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
33452110 2021. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
33425074 2021. Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19.
33423905 2021. Flying higher than politics: The goal of preventive medicine at the time of the COVID-19 pandemic.
33486200 2021. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
33483798 2021. Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.
33464367 2021. Severe sinus bradycardia associated with remdesivir in a child with severe SARS-COV-2 infection-reply.
33428898 2021. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.
33387467 2021. Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations.
33482181 2021. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.
33497607 2021. Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2.
33509962 2021. Is high-dose glucocorticoid beneficial in COVID-19?
33511068 2020. Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh.
33381197 2020. Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4(th) Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking.
33500777 2020. Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approach.
33495727 2021. Polyphenols as promising biologically active substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms.
33418408 2021. An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2.
33412235 2021. Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study.
33435315 2021. Probiotic Effects against Virus Infections: New Weapons for an Old War.
33475983 2021. Does herbal therapy for COVID-19 have implications for forensic practice?
33469529 2020. Nitric Oxide Releasing Hydrogel Nanoparticles Decreases Epithelial Cell Injuries Associated With Airway Reopening.
33426009 2020. Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update.
33392268 2020. Thromboinflammation and COVID-19: The Role of Exercise in the Prevention and Treatment.
33469541 2020. Combating COVID-19 With Mesenchymal Stem/Stromal Cell Therapy: Promise and Challenges.
33384971 2020. NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments.
33381464 2020. What Can Cellular Redox, Iron, and Reactive Oxygen Species Suggest About the Mechanisms and Potential Therapy of COVID-19?
33425850 2020. Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2.
33488592 2020. Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.
33424848 2020. COVID-19: Coronavirus Vaccine Development Updates.
33424838 2020. The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19.
33408715 2020. Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19.
33391285 2020. A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters.
33425942 2020. Humidified Warmed CO2 Treatment Therapy Strategies Can Save Lives With Mitigation and Suppression of SARS-CoV-2 Infection: An Evidence Review.
33415116 2020. The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective.
33490110 2020. Molecular Docking and Molecular Dynamics Aided Virtual Search of OliveNet Directory for Secoiridoids to Combat SARS-CoV-2 Infection and Associated Hyperinflammatory Responses.
33425995 2020. Exploring the Potential of Carbon Dots to Combat COVID-19.
33425994 2020. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL(pro).
33392263 2020. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic.
33392261 2020. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.
33381519 2020. Potential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019.
33505983 2020. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study.
33385008 2020. Probiotics as a Weapon in the Fight Against COVID-19.
33489899 2020. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.
33447586 2020. Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome.
33442386 2020. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.
33424586 2020. Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection.
33390999 2020. Commentary: Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.
33390994 2020. COVID-19 Disease and Vitamin D: A Mini-Review.
33390974 2020. Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.
33390967 2020. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.
33390952 2020. Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2.
33390948 2020. The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.
33384605 2020. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.
33505321 2020. Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial.
33424618 2020. The Effects of Displacing Sedentary Behavior With Two Distinct Patterns of Light Activity on Health Outcomes in Older Adults (Implications for COVID-19 Quarantine).
33490659 2021. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?
33462562 2021. Traditional foods with their constituent's antiviral and immune system modulating properties.
33458435 2021. In silico validation of potent phytochemical orientin as inhibitor of SARS-CoV-2 spike and host cell receptor GRP78 binding.
33421583 2021. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis.
33473017 2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.
33448317 2021. Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in interferon signaling and COVID19 (Review).
33491759 2021. Immune-checkpoint inhibitors from cancer to COVID19: A promising avenue for the treatment of patients with COVID19 (Review).
33523564 2021. Emerging COVID-19 vaccines: A rheumatology perspective.
33517559 2021. Adverse drug reactions in SARS-COV-2 hospitalised patients: a case series with a focus on drug-drug interactions-comment.
33521604 2021. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.
33388478 2020. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.
33524876 2021. COVID-19 convalescent plasma composition and immunological effects in severe patients.
33519133 2021. An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid-19 -A Randomized Controlled Study.
33519134 2020. Pathophysiology of COVID-19 and Host centric approaches of Ayurveda.
33518853 2021. Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease.
33518802 2021. In silico assessment and sonochemical synthesis of 2-alkynyl 3-chloropyrazines as prospective ligands for SARS-CoV-2.
33518801 2021. Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19.
33518803 2021. Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies.
33493479 2021. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model.
33523655 2021. Retrained Generic Antibodies Can Recognize SARS-CoV-2.
33508197 2021. On Drug-Membrane Permeability of Antivirals for SARS-CoV-2.
33439735 2021. Butyrate Regulates COVID-19-Relevant Genes in Gut Epithelial Organoids From Normotensive Rats.
33406943 2021. Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility.
33390092 2021. The impact of probiotics on interactions within the microbiota-gut-lung triad in COVID-19.
33435749 2021. Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19.
33488303 2020. Opportunities for Health Promotion: Highlighting Herbs and Spices to Improve Immune Support and Well-being.
33500022 2021. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
33510536 2021. COVID-19 Vaccine Development to Vaccination.
33509969 2021. LETTER TO THE EDITOR: ON POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.
33483330 2021. COVID-19 Vaccination: An Overview and Education Tool for Nuclear Medicine Technologists.
33455524 2021. Clinical Consideration of Glucocorticoids in COVID-19.

33447376 2020. Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.
33447372 2020. Computational screening for potential drug candidates against the SARS-CoV-2 main protease.
33519469 2020. Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives.
33519467 2020. 3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor.
33519463 2020. TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target.
33519460 2020. Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19.
33519449 2020. A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection.
33490124 2020. The Strategy of Boosting the Immune System Under the COVID-19 Pandemic.
33457429 2021. Compounds of Citrus medica and Zingiber officinale for COVID-19 inhibition: in silico evidence for cues from Ayurveda.
33415989 2021. Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database.
33404263 2020. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.
33432269 2020. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective.
33387518 2021. Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19.
33484690 2021. Reply: The New Foe and Old Friends: Are We Ready for Microbiota-based Therapeutics in Treating COVID-19 Patients?
33453230 2021. Reply.
33388317 2020. Letter to the editor: Famotidine and mortality in COVID-19.
33387529 2020. Famotidine and COVID-19.
33487665 2021. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.
33428154 2021. Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis.
33413610 2021. An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets.
33482326 2021. Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy.
33412759 2020. Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2.
33432441 2021. PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19.
33386081 2021. Network machine learning maps phytochemically rich "Hyperfoods" to fight COVID-19.
33426490 2021. Editorial Comment to Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.
33465283 2021. Efficacy of canakinumab in mild or severe COVID-19 pneumonia.
33418320 2021. BCG immunomodulation: From the 'hygiene hypothesis' to COVID-19.
33492637 2021. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.
33397150 2021. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
33432283 2021. Evaluation of certain medicinal plants compounds as new potential inhibitors of novel corona virus (COVID-19) using molecular docking analysis.
33425648 2021. In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M(pro)).
33425647 2021. Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach.
33437070 2020. Hyperbaric oxygen therapy: Can it be a novel supportive therapy in COVID-19?
33495676 2021. COVID-19 and Gut Microbiota: A Potential Connection.
33384519 2020. Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials.
33384506 2020. A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital.
33384504 2020. Immunomodulation and COVID-19: Is There a Winning Combination?
33446983 2020. Intravenous Immunoglobulin may Reverse Multisystem Inflammation in COVID-19 Pneumonitis and Guillain-Barre Syndrome.
33424043 2021. Restoring Good Health in Elderly with Diverse Gut Microbiome and Food Intake Restriction to Combat COVID-19.
33390627 2020. Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19.
33469896 2021. BCG Vaccination Protection Against COVID-19: Correspondence.
33484407 2021. The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort.
33500636 2021. Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.
33422682 2021. Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19.
33495884 2021. Worldwide inverse correlation between Bacille Calmette-Guerin (BCG) immunization and COVID-19 mortality.
33389708 2021. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.
33521241 2021. Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease.
33457495 2021. In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19).
33521757 2021. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir.
33524979 2021. Principles and Challenges in anti-COVID-19 Vaccine Development.
33476982 2021. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review.
33450596 2021. Different characteristics of critical COVID-19 and thinking of treatment strategies in non-elderly and elderly severe adult patients.
33429331 2021. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.
33418248 2021. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.
33412395 2021. Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
33421928 2021. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study).
33515687 2021. Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals.
33476734 2021. Reply to the letter to the editor "Azithromycin, treatment in COVID-19".
33476733 2021. Azithromycin, a questionable treatment for COVID-19.
33400975 2021. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
33408033 2021. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
33408032 2021. Advanced statistical methods and designs for clinical trials for COVID-19.
33408031 2021. Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
33408029 2021. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
33408028 2021. Response to advances statistical methods and designs for clinical trials for COVID-19.
33408027 2021. Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
33408026 2021. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
33408025 2021. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
33408024 2021. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
33408022 2021. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
33408021 2021. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
33408020 2021. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
33408019 2021. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
33408018 2021. Doxycycline as an Alternative to Azithromycin in Elderly Patients.
33408017 2021. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
33405321 2021. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis.
33417696 2021. Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma.
33411937 2021. Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer.
33433587 2021. Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19.
33511686 2021. Tocilizumab in COVID-19 interstitial pneumonia.
33520685 2021. Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach.
33520684 2021. Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods.
33520683 2021. Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection.
33520682 2021. Molecular docking analysis of rutin reveals possible inhibition of SARS-CoV-2 vital proteins.
33521616 2021. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
33480414 2021. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
33516648 2021. Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.
33521397 2021. Integrating Integrins: A New Way to Increase Our COVID-19 Armamentarium?
33518628 2021. Inactivation of SARS-CoV-2 by Catechins from Green Tea.
33518623 2021. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
33524312 2021. Next-generation COVID-19 vaccines: here come the proteins.
33524311 2021. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
33521772 2021. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.
33521771 2021. Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?
33521768 2020. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults.
33521732 2021. COVID-19 vaccines: the pandemic will not end overnight.
33463480 2021. The Role of Justicia Adhatoda as prophylaxis for COVID-19 - Analysis based on docking study.
33493866 2021. Ergosterol peroxide exhibits antiviral and immunomodulatory abilities against porcine deltacoronavirus (PDCoV) via suppression of NF-kappaB and p38/MAPK signaling pathways in vitro.
33414160 2021. Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.
33414159 2021. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
33468542 2021. The time for COVID-19 vaccination.
33441348 2021. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.
33507218 2021. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.
33404587 2021. Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk.
33464336 2021. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
33404585 2021. Problems With Paying People to Be Vaccinated Against COVID-19.
33475702 2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.
33475716 2021. Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19.
33475701 2021. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
33512398 2021. Can We Protect Pregnant Women and Young Infants From COVID-19 Through Maternal Immunization?
33515791 2021. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
33444566 2021. Vitamin D and COVID-19: why the controversy?

33392487 2021. Cyclosporine A and COVID19 - The COQUIMA cohort - Author's reply.
33392485 2021. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
33385129 2021. Cyclosporine A and COVID-19 - The COQUIMA cohort.
33385128 2021. Cyclosporine A and COVID19 - The COQUIMA cohort.
33385124 2021. Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials.
33471720 2020. Considerations for Gut Microbiota and Probiotics in Patients with Diabetes Amidst the Covid-19 Pandemic: A Narrative Review.
33380209 2020. Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients.
33452994 2021. Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D.
33413989 2020. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.
33401173 2021. A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2.
33387537 2021. Urinary trace elements in association with disease severity and outcome in patients with COVID-19.
33447984 2021. Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.
33427370 2021. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
33520339 2020. Lifestyle factors in the prevention of COVID-19.
33387629 2021. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
33408016 2021. Can we use hydroxychloroquine to treat COVID-19 now?
33408015 2021. Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
33408014 2021. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
33515771 2021. Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study.
33493690 2021. A short discussion about the SARS-CoV-2 mRNA-1273 vaccine.
33476760 2021. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
33401034 2021. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis.
33385581 2021. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study.
33434674 2021. Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching.
33437199 2021. Clinical characteristics and impacts of traditional Chinese medicine treatment on the convalescents of COVID-19.
33390810 2021. DCs-based therapies: potential strategies in severe SARS-CoV-2 infection.
33390800 2021. Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy.
33416113 2021. Unraveling the roles of vitamin D status and melanin during Covid19 (Review).
33498909 2021. Membrane Microvesicles as Potential Vaccine Candidates.
33488318 2021. Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation.
33427662 2020. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia.
33460304 2020. Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global Rheumatology Alliance Registry.
33487035 2021. The coronavirus disease (COVID-19) - A supportive approach with selected micronutrients.
33425283 2021. Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2.
33488306 2020. The Long Haul of COVID-19 Recovery: Immune Rejuvenation versus Immune Support.
33507321 2021. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply.
33388793 2021. Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.
33398609 2021. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs.
33400161 2021. The need for a correct oxygen-ozone autohemotherapy (O3-AHT) in patients with mild to moderate COVID-19 pneumonia.
33400157 2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
33390490 2021. Immediate Amelioration of Severe Respiratory Distress in Sjogren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab.
33409846 2021. Active vitamin D supplementation and COVID-19 infections: review.
33409844 2021. Step zero: optimising nutrition for physical and mental health wellbeing during COVID-19.
33433843 2021. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
33490902 2021. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance.
33426509 2021. A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening.
33443334 2021. Convalescent Whole Blood Donors Screening Strategies for Providing Efficient and Safe COVID-19 Survivors' Plasma and Other Blood Components.
33425697 2020. The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness.
33485650 2021. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.
33482251 2021. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.
33440213 2021. Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis.
33492492 2021. Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus.
33524316 2021. SARS-CoV-2 evolution and vaccines: cause for concern?
33521656 2021. Divergent effects of acute versus chronic glucocorticoids in COVID-19.
33521667 2021. Hydroxychloroquine in the prevention of COVID-19 mortality.
33521676 2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 - Authors' reply.
33521675 2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19.
33521674 2021. Efficacy matters: broadening complement inhibition in COVID-19.
33521673 2021. Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.
33521663 2020. Mavrilimumab for severe COVID-19 - Authors' reply.
33521662 2020. Mavrilimumab for severe COVID-19.
33521661 2020. Mavrilimumab for severe COVID-19.
33521660 2020. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.
33521666 2020. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?
33491234 2021. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.
33459118 2021. Antibodies to watch in 2021.
33520672 2021. FDA Recommended Potent Drugs against Covid-19: Insight through Molecular Docking.
33521747 2021. A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice.
33521295 2021. Unresolved questions about the treatment of COVID-19 with corticosteroids.
33521297 2020. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.
33521304 2020. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
33521302 2020. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
33521623 2021. AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate.
33520634 2021. Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
33460213 2021. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.
33519030 2020. Nutricion y pandemia de la COVID-19.
33524563 2021. Inhibitory efficiency of potential drugs against SARS-CoV-2 by blocking human angiotensin converting enzyme-2: Virtual screening and molecular dynamics study.
33520405 2021. Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19.
33523609 2021. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
33509749 2021. [Mechanism and material basis of Lianhua Qingwen capsule for improving clinical cure rate of COVID-19: a study based on network pharmacology and molecular docking technology].
33497482 2021. Germicidal UV Sources and Systems(dagger).
33438214 2021. Bare-bulb Upper-Room Germicidal Ultraviolet-C (GUV) Indoor Air Disinfection for COVID-19(dagger).
33511704 2021. Spices and herbs: Potential antiviral preventives and immunity boosters during COVID-19.
33452734 2021. Exploring the treatment of COVID-19 with Yinqiao powder based on network pharmacology.
33448101 2021. In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro).
33524017 2021. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
33524041 2021. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.
33427193 2021. Nutritional knowledge, attitude and behaviours regarding Coronavirus Disease 2019 among residents of Gonabad, Iran.
33416888 2021. Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy.
33482671 2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen, Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphanomene, Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.
33524996 2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19, weitere Impfstoff-Kandidaten und assoziierte Immunphanomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.
33429407 2020. Timing of remdesivir for COVID-19.
33443491 2020. Remdesivir (Veklury) for COVID-19.
33443490 2020. An EUA for bamlanivimab - a monoclonal antibody for COVID-19.
33451175 2020. An EUA for baricitinib (Olumiant) for COVID-19.
33451174 2020. An EUA for casirivimab and imdevimab for COVID-19.
33393116 2021. Therapeutic targets and potential agents for the treatment of COVID-19.
33382060 2020. Terapias celulares para el COVID-19: Una revision sistematica viva.
33397236 2021. A mini review on emerging targets and Approaches for the synthesis of Anti-Viral compounds: In perspective to COVID-19.
33405340 2021. QSAR Modeling of SARS-CoV M(pro) Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2.
33513050 2021. How IvIg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model.
33400280 2020. Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
33400277 2020. Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
33432224 2021. Hunt for improved monoclonals against coronavirus gathers pace.
33432247 2021. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent.
33494096 2021. Global absence and targeting of protective immune states in severe COVID-19.
33514888 2021. How to redesign COVID vaccines so they protect against variants.
33510489 2021. Novavax offers first evidence that COVID vaccines protect people against variants.
33471372 2021. Extreme Exposure to Filtered Far-UVC: A Case Study.
33389761 2021. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial.
33507610 2021. Phytotherapeutic options for the treatment of COVID-19: A concise viewpoint.
33452160 2021. Vitamin D and COVID-19: causal factor or bystander?

33434117 2021. Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19.
33487918 2020. Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining.
33413968 2021. 'BhAVI-23'-A spice-herb based dietary infusion possessing in-vitro anti-viral potential.
33491541 2021. Drivers of Infectious Disease Seasonality: Potential Implications for COVID-19.
33495424 2020. The prognosis and short-term efficacy of corticosteroid therapy for COVID-19 patients.
33397223 2021. Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV.
33397209 2021. Molecular mechanism of inhibition of COVID-19 main protease by beta-adrenoceptor agonists and adenosine deaminase inhibitors using in silico methods.
33478342 2021. In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.
33475021 2021. In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase.
33459192 2021. An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease.
33459182 2021. Identification of 1,2,3-triazole-phthalimide derivatives as potential drugs against COVID-19: a virtual screening, docking and molecular dynamic study.
33446077 2021. Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2.
33446058 2021. Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors.
33438525 2021. Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study.
33427588 2021. Predictive medicinal metabolites from Momordica dioica against comorbidity related proteins of SARS-CoV-2 infections.
33382023 2020. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study.
33382021 2020. Virtual repurposing of ursodeoxycholate and chenodeoxycholate as lead candidates against SARS-Cov2-Envelope protein: A molecular dynamics investigation.
33423911 2021. Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient.
33426541 2020. Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19.
33468620 2021. Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor.
33474624 2021. C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.
33458752 2020. Relationship Between Dietary Variety and Frailty in Older Japanese Women During the Period of Restriction on Outings Due to COVID-19.
33476835 2021. Convalescent plasma: Alternative or promising therapy?
33460844 2021. Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2.
33385588 2021. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
33441177 2021. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
33426096 2020. Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs.
33402301 2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.
33493919 2021. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
33493917 2021. The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.
33486372 2021. Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2.
33509217 2021. Anti-inflammatory potential of Quercetin in COVID-19 treatment.
33447071 2021. Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.
33414643 2020. Calcio-Herbal Medicine Divya-Swasari-Vati Ameliorates SARS-CoV-2 Spike Protein-Induced Pathological Features and Inflammation in Humanized Zebrafish Model by Moderating IL-6 and TNF-alpha Cytokines.
33433387 2021. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines.
33393485 2021. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
33432258 2021. Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations.
33390681 2021. Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (M(pro)): DFT, QSAR, molecular docking, and in silico toxicity analysis.
33463095 2021. The Impact of the Coronavirus Disease-2019 Pandemic on Childhood Obesity and Vitamin D Status.
33425294 2020. Computational Biology Analysis of COVID-19 Receptor-Binding Domains: A Target Site for Indocyanine Green Through Antimicrobial Photodynamic Therapy.
33425284 2020. Application of Laser Blue Light With a Wavelength of 405 nm in the Treatment of Patients With the Virus COVID-19.
33500211 2021. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
33390633 2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part I: Complexation with iodine in different solvents.
33390634 2021. Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations.
33500591 2021. Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease.
33390613 2021. Synthesis of novel indolo[3,2-c]isoquinoline derivatives bearing pyrimidine, piperazine rings and their biological evaluation and docking studies against COVID-19 virus main protease.
33424034 2021. Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment.
33457350 2020. Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India.
33493945 2021. Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk.
33437230 2021. In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants.
33443088 2021. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
33497729 2021. Antiviral activity of bioactive phytocompounds against coronavirus: An update.
33417058 2021. A case of shock after 10 days systemic corticosteroid therapy for COVID-19.
33478708 2021. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
33427208 2021. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
33476300 2021. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
33520251 2021. Chloroquine and COVID-19: role as a bitter taste receptor agonist?
33518950 2020. Can vitamin D offer protection against the coronavirus?
33494567 2021. Vitamin D in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with non-invasive ventilation support.
33520633 2021. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.
33520632 2021. Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.
33518780 2021. inverted question markEs la nutricion el factor de riesgo olvidado en la infeccion por COVID-19?
33519022 2021. Principales desafios del desequilibrio electrolitico en pacientes geriatricos con COVID-19 y riesgo de prolongacion del intervalo QT.
33382930 2020. Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings.
33515320 2021. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.
33502499 2021. Baricitinib set to join the Covid-19 therapeutic arsenal?
33519274 2021. Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic?
33519272 2021. In-silico network-based analysis of drugs used against COVID-19: Human well-being study.
33519276 2021. In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell line.
33519275 2021. Potential bangle (Zingiber montanum J.Konig) rhizome extract as a supplement to prevent and reduce symptoms of Covid-19.
33519339 2021. Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.
33519336 2021. Convalescent Plasma in COVID-19: To what Degree should Clinicians Rely on Currently Available Data?
33397677 2021. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals.
33514629 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
33495306 2021. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
33495308 2021. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
33495307 2021. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
33436526 2021. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
33436524 2021. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
33516820 2021. Edible plant-derived exosomal microRNAs: Exploiting a cross-kingdom regulatory mechanism for targeting SARS-CoV-2.
33483756 2021. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
33518427 2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review.
33518428 2021. WITHDRAWN: New Generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
33458811 2021. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
33448402 2021. Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.
33521322 2021. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.
33523551 2021. Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.
33519087 2021. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic.
33519086 2020. Food policy, nutrition and nutraceuticals in the prevention and management of COVID-19: Advice for healthcare professionals.
33522946 2021. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).
33516600 2021. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
33524990 2021. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
33481519 2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).
33481518 2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).
33411888 2021. Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development.
33401979 2021. Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase.
33423931 2021. Copper in infectious disease: Using both sides of the penny.
33482680 2021. Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-analysis.
33443365 2021. H2S As A Therapeutic Adjuvant Against COVID-19: Why and How?
33448169 2020. [Mechanism and intervention of mucosal immune regulation based on "lung and large intestine being interior-exteriorly related" theory of traditional Chinese medicine].
33415866 2020. [Effect of moxibustion on clinical symptoms, peripheral inflammatory indexes and T lymphocyte subsets in COVID-19 patients].
33496147 2020. [Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection].
33463485 2020. [Effectiveness of convalescent plasma for treatment of coronavirus disease 2019 patients].